Consistently, mice inoculated with 10,000, 1,000, or 100 p53/BRCA1-deficient tumor organoid cells and treated with TcdBFBD survived 1.2 days (P = 0.014), 14.84 days (P = 0.001), or 22.88 days (P = 0.017) longer than those treated with vehicle or TcdBmu (Fig 5G). Here, TP53 is linked to neoplasm.